Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
about
Second-generation antipsychotics and extrapyramidal adverse effectsNew and emerging treatments for symptomatic tardive dyskinesiaPharmacogenetics and outcome with antipsychotic drugsMechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part IITardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics.Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs.Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges.Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report.Estimating the optimal dynamic antipsychotic treatment regime: Evidence from the sequential multiple assignment randomized CATIE Schizophrenia Study.Tardive dyskinesia and essential fatty acids.Tardive dyskinesia: treatment with aripiprazole.Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations.High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature.Treatment of neurolept-induced tardive dyskinesiaCan atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.Tardive dyskinesia with clozapine dose reduction or withdrawal dyskinesia?Aripiprazole-induced Tardive Dyskinesia in 13 Years Old Girl Successfully Treated with Biperiden: A Case Report.Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Suppression of antipsychotic-induced tardive dyskinesia with aripiprazole in an elderly patient with bipolar I disorder.Breakthrough drugs for the interface between psychiatry and neurology.
P2860
Q21284676-70CB0CD1-8624-4BEE-B911-75B9972C9B02Q24599912-C32F8C0A-2BA2-457C-A2BF-8A4485C8EB6DQ26852807-764C0CFF-48BC-4E07-A6FF-C325DC57B612Q33612521-EA043921-FEE7-45CE-A3B6-89C67076FD24Q34388086-E53CA6E7-7FF3-46A6-8BDE-C015781D0620Q34541147-2CDD33A4-BD70-425C-832C-1DB5DDA84587Q34823805-EBBC6CAE-4552-4E7C-BA7D-9E6658DB466AQ35813662-EC9242EE-B48F-40C7-A3FC-E981BA05FC87Q36330858-F52602C2-EFE2-4899-AAE3-8B6084287C55Q36508056-FE0F64D7-FB0B-4179-8A70-C4CE41433FAAQ36599203-8BE09328-37E1-4D18-8D18-4CC3BF1DDD69Q36806137-BA10F2F8-E28B-4ED6-808D-AA4113AAC1FCQ36816763-85DB2418-FCBE-4CBD-8CF3-0808488BC3B2Q37198420-EB4C2D7B-9F0A-48EC-989D-B0D0B97394C8Q37460501-AB862D3C-82AE-494B-BEF1-F03CCCB814D2Q38545655-820F4BCF-9A95-4AA8-946E-3F840F01D835Q38789841-F86AF40B-B7D7-4BDD-9A31-FD34BE1A4C73Q38819771-CA3F9C27-DD9C-4BB9-9D7C-F94A3FFF29E2Q39065466-D34E7A22-2BF6-42C3-9641-D793389B1A64Q39396657-370A3622-9512-4CB0-8029-3DCC1CF101E3Q41903201-4037290D-C4A2-44CD-8F7B-DC7774EE7E71Q42348171-0837360A-EF0C-4DC3-96FF-D6894F1F3A2DQ47675010-9C41703D-2E24-4157-91D7-007CF4DBB74BQ48035618-5FECEA87-E72F-4599-99B9-439FCBB94334Q55059642-ED54BBD3-8B41-4DDA-A0E9-B55ECBCC0CF5
P2860
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Tardive dyskinesia in the era ...... n patients with schizophrenia.
@ast
Tardive dyskinesia in the era ...... n patients with schizophrenia.
@en
type
label
Tardive dyskinesia in the era ...... n patients with schizophrenia.
@ast
Tardive dyskinesia in the era ...... n patients with schizophrenia.
@en
prefLabel
Tardive dyskinesia in the era ...... n patients with schizophrenia.
@ast
Tardive dyskinesia in the era ...... n patients with schizophrenia.
@en
P2093
P2860
P1476
Tardive dyskinesia in the era ...... n patients with schizophrenia.
@en
P2093
Guy Chouinard
Howard C Margolese
Lawrence Annable
Linda Beauclair
Robert Miller
Theodore T Kolivakis
P2860
P304
P356
10.1177/070674370505001110
P407
P577
2005-10-01T00:00:00Z